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Background: Diagnosis of a biliary stricture often hinges on cytological interpretation. In the absence of
accompanying stroma, these results can often be equivocal. In theory, advanced shave biopsy tech-
niques would allow for the preservation of tissue architecture and a more accurate definition of biliary
pathology.
Objectives: We sought to determine the initial diagnostic utility of the modern Silverhawk™ atherectomy
(SA) catheter in the evaluation of biliary strictures that appear to be malignant.
Methods: A total of 141 patients with biliary pathology were identified during a retrospective review of
medical records for the years 2006–2011. The SA catheter was employed 12 times in seven patients for
whom a tissue diagnosis was otherwise lacking.
Results: Neoplasia was definitively excluded in seven specimens from four patients. These four indi-
viduals were followed for 1–5 years to exclude the development of cholangiocarcinoma (CC). Samples
were positive for CC in three patients, one of whom became eligible for neoadjuvant therapy and
orthotopic liver transplantation.
Conclusions: The SA catheter appears to be a useful adjunct in diagnosing patients with biliary
pathology. The existence of this technique, predicated on tissue architecture, may impact therapy, allow
more timely diagnosis, and exclude cases of equivocal cytology. Although the initial results of SA use are
promising, more experience is required to effectively determine its clinical accuracy.
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Introduction
In the setting of a biliary stricture that appears to be malignant, a
tissue diagnosis of cholangiocarcinoma (CC) informs all subse-
quent decision making. Although contemporary advances in
endoscopic retrograde cholangiopancreatography (ERCP) tech-
nology and endoscopic accessories have made non-operative
treatment a viable alternative in even the most complicated of
biliary pathology, definitive evidence of neoplasia can trans-
form an expectant management paradigm into one in which the
possibility of resection or, more recently, orthotopic liver trans-
plantation (OLT), becomes the primary focus.1 In both scenarios,
outcomes are much improved by the early detection of disease.2–5
Early detection of CC, however, is a formidable challenge. Current
diagnostic approaches offer suboptimal yield and must rely on a
combination of serological testing, imaging modalities, cytologi-
cal analyses and a high index of clinical suspicion.6 Pathological
diagnosis, however, remains the reference standard. In this
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context, endoscopic over-the-wire brush sampling of suspicious
biliary lesions is frequently performed as the primary diagnostic
procedure, allowing for the characterization of biliary epithelia as
benign, atypical, or overtly malignant-appearing. However, as
sensitivities range from 20% to 60%, these samples are not
always confirmatory and are sometimes difficult to acquire.7–9
Because the maintenance of tissue architecture and preserva-
tion of stroma are fundamental components of pathological diag-
nosis, biopsy techniques incorporating greater amounts of biliary
tissue have at least the potential to improve diagnostic yield when
cytology is otherwise equivocal. This has been demonstrated most
recently in the use of endoscopic forceps biopsy, especially when it
is combined with biliary brushings, and in some cases has doubled
diagnostic sensitivity.9
Interestingly, the Simpson Atherocath™ (Devices for Vascular
Intervention, Inc., Redwood City, CA, USA), a device originally
intended for use in the treatment of atherosclerotic occlusive
disease by means of percutaneous atheroma removal, was appro-
priated by Kim et al. over two decades ago for biopsy of common
bile duct lesions via a percutaneous transhepatic approach.10 This
was followed by two demonstrations of the high diagnostic yield of
the technique in the setting of biliary strictures.11,12 Since its
approval in 1990 by the US Food and Drug Administration (FDA)
for directional coronary plaque excision, numerous improvements
in catheter design have followed,13 culminating in the present-day
Silverhawk™ SXL plaque excision system (FoxHollow Technolo-
gies, Inc., Redwood City, CA, USA). This device was approved by
the FDA in 2007, and is now the leading directional atherectomy
catheter on themarket.14 Lacking an apposition balloon, the Silver-
hawk™device self-apposes using a hinge system,contains a carbide
cutter with variable height, and can rotate at speeds of up to
8000 rpm. The device is utilized over a commonly available
guidewire (0.014-inch) in a ‘monorail’ configuration. It is also
smaller and contains a palm-sized drive unit that permits conve-
nient single-operator use. Additionally, the hinged nose cone can
act as a large depository for intraluminal contents, with collection
occurring distally to the cutting mechanism.Using this, the opera-
tor can decide the extent of the application and the large chamber
size can facilitate its application over longer distances.14 These
improvements not only make the device more attractive in the
coronary and peripheral vascular arenas, but also offer theoretical
advantages in hepatobiliary applications. Since 2006, we have used
the Silverhawk™ atherectomy (SA) catheter in situations in which
conventional diagnostic approaches to biliary lesions have proven
equivocal. In this report,we catalogue thefirst clinical experienceof
use of the SA catheter for hepatobiliary indications.
Materials and methods
A total of 141 patients with suspicious biliary pathology were
identified upon a retrospective review of multidisciplinary treat-
ment conference records (diagnostic radiology, interventional
radiology, hepatobiliary or transplant surgery, hepatology, pathol-
ogy, medical oncology, radiation oncology) for the year 2006–
2011. Of the total, 78 patients had documented CC. Of those for
whom complete documentation was available, 31 were noted to
have peripheral (non-hilar) CC; the remainder had either a hilar
stricture with or without an associated mass (n = 29), or a malig-
nant lesion of the extrahepatic bile ducts (n = 18). Of the patients
with CC, 14% had a concomitant diagnosis of either primary
sclerosing cholangitis (PSC) or inflammatory bowel disease.
Patients in the non-CC group had either benign pathology (n =
23) or pancreatic cancer (n = 7). Data for the remainder showed
metastatic neuroendocrine tumour (n = 1), papillary adenoma
(n = 1), or were inconclusive (n = 1).
Procedural details
All patients undergoing the procedure were given antibiotics as
prophylaxis against cholangitis and i.v. sedation with fentanyl
citrate and midazolam hydrochloride prior to and during the
procedure. Two to eight weeks prior to the biopsy procedure, an
ultrasound or fluoroscopically guided percutaneous transhepatic
cholangiogram (PTC) was performed. An 8–12-Fr internal/
external biliary drainage catheter was advanced across the suspi-
cious areas in the biliary tree and into the duodenum. Right- or
left-sided access was selected according to clinical needs and
imaging. Patients were typically admitted for overnight observa-
tion after initial percutaneous access. Prior to the biopsy proce-
dure, all anticoagulants and antiplatelet medications were
discontinued and bleeding risks were mitigated as well as possible.
To perform the procedure, the indwelling drainage catheter was
removed over a 0.035-inch guidewire. A 9–10-Fr vascular sheath
was then inserted through the biliary tree and into the duodenum.
A pull-back cholangiogram was performed and the target
lesion(s) identified. The wire was replaced with a 0.014-inch
interventional-type stiff body guidewire. A large vessel Silver-
hawk™ LX or LM atherectomy catheter was advanced over the
wire, through the sheath, and into a position distal to the target
lesion. The sheath was then pulled back, exposing the cutting
surface of the device to the mucosa. Contrast medium was
injected as needed to delineate the target. The device was actuated
by advancing it slowly over the wire and across the target. Biopsy
was performed by pulling back while simultaneously rotating
the device. In this manner, multiple circumferential biopsies
were obtained (Fig. 1). Typically, between three and 12 passes were
made depending upon the amount of tissue to be removed. Ease
of removal and re-insertion was facilitated by the rapid-exchange
monorail design of the device. Usually, the procedure was
terminated when 0.2-cm tissue plugs totalling 5–8 cm in length
had been removed (Fig. 1). Finally, a completion cholangiogram
was performed through the sheath and a new 10–14-Fr internal/
external biliary drain was inserted. Following the procedure, all
patients were monitored every 1–4 h depending on the technical
difficulty of the procedure, the patient’s clinical status, and
whether haemobilia was present. Transhepatic catheters were left
to drain externally and capped the next day. Criteria for discharge
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post-procedure included haemodynamic stability, absence of cho-
langitis symptoms, and biliary drainage with no discernable signs
of haemorrhage. Patients were instructed to flush the tube with
10 ml of sterile saline each day and received longterm follow-up
with at least one of the clinical services referred to above.
Results
Patient overview
Table 1 presents an overview of the patient series. The SA catheter
was employed 12 times in seven patients in whommalignancy was
suspected, but a definitive tissue diagnosis was lacking. These
individuals ranged in age from 49 years to 76 years (mean age: 62
years). Four patients were male; three were female. Three patients
had known PSC. Prior to the use of the SA catheter, all patients
underwent computed tomography (CT) of the abdomen and/or
magnetic resonance imaging (MRI) with cholangiopancreatogra-
phy as part of their workup. All but one patient lacked evidence of
a hilar mass on cross-sectional imaging. According to the Bismuth
– Corlette classification system,15 biliary strictures were classed as
types I (n = 1), II (n = 2), IIIb (n = 2) and IV (n = 2). As in other
patients with biliary pathology, ERCP with intraluminal brush
cytology was the method preferred to obtain a tissue diagnosis in
these individuals. However, endoscopic brushings were obtained
in only two individuals because in the remaining cases, a portion
of the biliary tree could not be accessed by endoscopic means. This
necessitated percutaneous transhepatic intubation for biliary
sampling or relief of obstruction in six individuals. Of the patients
in whom percutaneous access was attempted, over-the-wire
brushings prior to deploying the atherectomy device were per-
formed in two patients. One patient (Patient 3) arrived at our
institution with percutaneous biliary access already in place,
which greatly facilitated an atherectomy approach as the initial
diagnostic procedure.
Endoscopic or percutaneous cytological results, when obtained,
were negative, equivocal or demonstrated reactive epithelial atypia.
To secure a diagnosis, an atherectomy approach was employed in
two individuals (Patients 1 and 2) who demonstrated clinical
deterioration (new-onset pruritus, rapidweight loss, inantition) or
stricture progression (Patient 7) despite normal cytology and CA
19-9 levels. A third patient with dramatically elevated CA 19-9
underwent the procedure when brush cytology was negative in the
setting of equivocal fluorescence in situ hybridization (FISH)
results (Patient 4). In one instance (Patient 5), the technique was
a
b
Figure 1 (a) The modern Silverhawk™ atherectomy catheter and
(b) a typical biliary biopsy obtained using this catheter
Figure 2 Bismuth – Corlette type II biliary stricture in a previously
healthy, 69-year-old man with a normal CA 19-9 level. A firm tissue
diagnosis was lacking despite numerous cytological brushings
and cholangioscopically directed biopsies. Stricture progression
prompted eventual percutaneous transhepatic cholangiography and
atherectomy catheter deployment to facilitate the collection of
an intact biliary specimen. Pathological examination was felt to be
unambiguous for cholangiocarcinoma. Based on the results, the
patient became eligible for orthotopic liver transplantation. Exami-
nation of the explanted liver revealed perineural invasion and
scattered foci of well-differentiated adenocarcinoma in the wall
of the common bile duct, the largest of which measured 0.2 cm.
The patient remains alive with no evidence of recurrence at 1 year
post-transplant
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used to delineate the cause of biliary obstruction in a patient with
a prior history of an upper gastrointestinal tractmalignancy and in
another to exclude neoplasia when cross-sectional imaging sug-
gested a malignant cause of obstruction (Patient 4).
Outcome of the procedure
In all seven patients, SA catheter biopsy was the primary means of
establishing or excluding a diagnosis of biliary malignancy.While
corroborating earlier cytological and imaging results, neoplasia
was definitively excluded in seven biopsy specimens. These four
individuals were followed for 1–5 years to exclude the develop-
ment of CC. Three of the patients harboured a concomitant diag-
nosis of PSC.Mean CA 19-9 level at the time of SA catheter biopsy
in these individuals was 33.5, compared with 406.7 in patients in
whom catheter biopsy was positive. The procedure was performed
multiple times in one individual because of strong clinical suspi-
cion and extensive stricturing of the biliary tree. Absence of neo-
plastic change was confirmed with each subsequent biopsy and
this patient remains alive and well. Follow-up procedures were
required in a further two patients when the initial sample was
non-diagnostic. Another patient with PSC in whom negative
results were obtained eventually underwent OLT for intrinsic liver
disease. Malignancy was absent in the explanted liver.
Samples were positive for CC in three patients, only one of
whom had a known hilar mass. One patient became eligible for
neoadjuvant therapy and OLT despite several earlier false negative
cytological results. The explant in this case demonstrated evidence
of CC. This patient remains alive without evidence of recurrence
at >1 year post-OLT (Fig. 2). In the second positive case, atherec-
tomy biopsy uncovered evidence of severe epithelial atypia and
CC was found in the second of two biopsies performed 4 days
apart after review by a senior cytopathologist; this patient has
since died. The technique was used in a third patient to establish a
diagnosis of CC prior to resection, and employed again to docu-
ment recurrence in the liver remnant after resection; this patient
subsequently died. In one additional non-equivocal case, the SA
catheter corroborated positive results obtained with conventional
brushings (data not shown). In our series, sufficient tissue was
obtained for interpretation in 10 of 12 applications.
Complications and longterm effects
Minor haemobilia resulted after two of the atherectomy biopsy
attempts and was treated by irrigation or use of a larger drain. On
one of these occasions (Patient 2), a particularly difficult percu-
taneous access procedure was complicated by inadvertent arterial
puncture, requiring emergent arterial embolization of a terminal
hepatic arterial branch. However, this was related to the difficulty
of the percutaneous access procedure and was not a function
of atherectomy catheter deployment. One patient (Patient 6)
required hospital admission for pain control at 1 day post-
procedure. As this patient had admitted to pain after her original
PTC and prior to atherectomy, it is unclear whether this was again
a function of percutaneous access in general or associated with the
SA catheter. None of the patients developed infectious complica-
tions as a direct result of the procedure. However, one patient
with multiple biliary instrumentations and a history of post-
cholecystectomy stricture (Patient 5) developed an intrahepatic
abscess 4.5 months after the atherectomy procedure. It is
unknown whether the atherectomy procedure in this patient con-
tributed to abscess formation or whether the abscess represented a
consequence of longstanding biliary obstruction and repeated
biliary manipulation.
All of the patients in whom the SA catheter was deployed
required routine tube exchanges in accordance with the standard
of care for those with percutaneous biliary access. Patients were
routinely stented or retained their percutaneous biliary drains
post-procedure, but none appear to have incurred longterm
sequelae from the procedure that would suggest progressive
scarring or a further predisposition to biliary obstruction. In fact,
two patients (Patients 1 and 6) evidenced an improvement in the
radiographic appearance of their benign strictures, with Patient
6 demonstrating patency of the biliary tree post-procedure.
Discussion
On many occasions, a combination of methods is required
to evaluate a suspicious biliary lesion. Although imaging and
serological testing remain vital components of the multimodal
approach to diagnosis, pathological evaluation is central to sub-
sequent management decisions. In many cases, rendering a defini-
tive diagnosis in the setting of suspicious biliary pathology is
predicated on intraluminal brush cytology, in which discrimina-
tion between dysplasia and overt malignancy can be difficult.
In reality, little may separate the two. This, coupled with a lack of
uniform interpretation of diagnostic criteria, has caused reported
sensitivities for brush cytology to vary widely. With sensitivities
typically ranging between 20% and 60%,7–9 inability to secure a
diagnosis with this technique can be influenced by a variety of
additional factors.As CCs are tumours of the bile duct epithelium,
those that fail to penetrate into the lumen (submucosal spread)
will not be sampled appropriately. Sampling error may also be
encountered as a result of the paucicellular, desmoplastic nature of
the surrounding environment in which these tumours frequently
arise. The chronic inflammatory milieu common to the biliary
tree in patients with PSC can introduce further ambiguity. Well-
differentiated tumours, such as mucinous and papillary types,
may also generate false negatives as these tumours are difficult to
interpret on cytology. Tumours may occur at sites that are difficult
to access and that obviate the use of various biopsy techniques. In
the end, collected material may be insufficient for analysis.7,9
At a cost of approximately US$3000, the SA catheter is a device
readily available to most interventional radiology departments.
Familiarity with its use in the peripheral vascular arena is often
cultivated by interventional radiologists during fellowship and is
directly transferable to hepatobiliary applications. For those who
are unfamiliar with its operation, the technique is rapidly learned
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and straightforward, requiring only a fundamental skill set in
interventional radiology as a prerequisite. Refinements in catheter
design have reduced the device profile, improved its trackability
and led to better ergonomics compared with earlier atherectomy
devices. These features offer the potential for enhanced sample
collection and a reduced likelihood of complications. Specifically,
the previous generation Atherocath™ obtained biopsy samples in
a radial direction, perpendicular to the long axis of the duct.
However, the contemporary SA catheter shaves parallel to the long
axis, thereby reducing the potential for significant haemobilia and
bile duct perforation. In addition, the SA catheter’s greater flex-
ibility allows greater ease of access to the left-sided biliary tree.
Stricture morphology notwithstanding, our results show that
the SA catheter can be utilized with a high likelihood of success
to establish a tissue diagnosis when a portion of the biliary tree
remains inaccessible to the endoscopist, or when histology is
equivocal or inconsistent with clinical expectations.We found the
technique particularly advantageous in patients with pre-existing
biliary access. At our institution, patients with a dominant stric-
ture, cellular irregularity or indeterminate results undergo repeat
ERCP and follow-up cytology at 3-month intervals, or more fre-
quently according to the degree of clinical suspicion. The contin-
ued presence of cytological atypia on these examinations or its
return after an intervening normal cytological result is another
common scenario in which we foresee the employment of this
technique. Drawbacks to the technique include the need for per-
cutaneous access and, by inference, interventional radiology capa-
bility. Other potential shortcomings are the increased invasiveness
of the procedure and the risk for complications, of which haemo-
bilia is the chief concern. Longterm biliary sequelae could not
be convincingly demonstrated in our small subset of patients.
Although such changes may be difficult to discern from the
natural history of most biliary disorders, further documentation is
not currently available. For these reasons, we continue to recom-
mend conventional intraluminal brush cytology as the primary
means of establishing a diagnosis when an apparently malignant
biliary stricture is encountered.
Although our experience was relatively small, sensitivity and
specificity were 100%. These figures are relevant given the emer-
gence of neoadjuvant protocols to facilitate OLT in patients with
CC. Given that eligibility for transplant is restricted to those with
stage I and II disease, early detection is mandatory.1 In this
context, endoluminal bile duct biopsy by SA catheter appears
to be effective in excluding or diagnosing CC in patients with
apparently malignant biliary strictures. Because it incorporates
underlying stroma and maintains tissue architecture (Fig. 3), the
availability of this technique may result in eventual cost savings by
obviating the need for subsequent non-diagnostic procedures.
Additionally, it may allow for earlier diagnosis, earlier opportuni-
ties for resection, and the more efficient use of limited donor
resources where protocols for OLT are available.
Although surgery continues to represent the primary treatment
for CC, favourable outcomes after resection or transplant begin
with early detection and a multimodal approach to care. Famil-
iarity with a wide array of diagnostic techniques is paramount to
success. This analysis of our initial experience demonstrates that:
(i) intraluminal biliary pathology can be accessed safely using the
modern SA catheter via a percutaneous approach, and (ii) the SA
catheter has a potential for higher diagnostic yield than conven-
tional techniques. Therefore, it would be reasonable to consider its
a
b
Figure 3 (a) Longitudinal section of a bile duct biopsy obtained using
the Silverhawk™ atherectomy catheter, demonstrating small glands
and nested cells. At high magnification, these were diagnostic of
adenocarcinoma. (Haematoxylin and eosin stain; original magnifica-
tion ¥90.) (b) Longitudinal section of a bile duct biopsy without
malignancy, but with an inflammatory infiltrate and fibrosis. (H&E
stain; ¥90)
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use in the setting of diagnostic uncertainty or when a portion
of the biliary tree is inaccessible to the endoscopist. Ultimately,
its utility can be determined only after additional experience is
gained in the clinical setting.However, awareness of this technique
may prove beneficial in select cases.
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